100 related articles for article (PubMed ID: 1971310)
1. Synthesis and biological evaluation of analogues of Pro-Leu-Gly-NH2 modified at the leucyl residue.
Johnson RL; Bontems RJ; Yang KE; Mishra RK
J Med Chem; 1990 Jun; 33(6):1828-32. PubMed ID: 1971310
[TBL] [Abstract][Full Text] [Related]
2. Synthesis of Pro-Leu-Gly-NH2 analogues modified at the prolyl residue and evaluation of their effects on the receptor binding activity of the central dopamine receptor agonist, ADTN.
Johnson RL; Rajakumar G; Yu KL; Mishra RK
J Med Chem; 1986 Oct; 29(10):2104-7. PubMed ID: 2876104
[TBL] [Abstract][Full Text] [Related]
3. Dopamine receptor modulation by Pro-Leu-Gly-NH2 analogues possessing cyclic amino acid residues at the C-terminal position.
Johnson RL; Rajakumar G; Mishra RK
J Med Chem; 1986 Oct; 29(10):2100-4. PubMed ID: 2876103
[TBL] [Abstract][Full Text] [Related]
4. Dopamine receptor modulation by conformationally constrained analogues of Pro-Leu-Gly-NH2.
Yu KL; Rajakumar G; Srivastava LK; Mishra RK; Johnson RL
J Med Chem; 1988 Jul; 31(7):1430-6. PubMed ID: 3385734
[TBL] [Abstract][Full Text] [Related]
5. Bicyclic thiazolidine lactam peptidomimetics of the dopamine receptor modulating peptide Pro-Leu-Gly-NH2.
Subasinghe NL; Bontems RJ; McIntee E; Mishra RK; Johnson RL
J Med Chem; 1993 Aug; 36(16):2356-61. PubMed ID: 8103113
[TBL] [Abstract][Full Text] [Related]
6. Conformation and activity of +H2-Pro-Leu-Gly-NH2 and its analogues modified at the leucyl residue.
Kim YJ; Han SJ; Kim SC; Kang YK
Int J Pept Protein Res; 1995 Nov; 46(5):381-90. PubMed ID: 8567182
[TBL] [Abstract][Full Text] [Related]
7. Synthesis and dopamine receptor modulating activity of unsubstituted and substituted triproline analogues of L-prolyl-L-leucyl-glycinamide (PLG).
Baures PW; Pradhan A; Ojala WH; Gleason WB; Mishra RK; Johnson RL
Bioorg Med Chem Lett; 1999 Aug; 9(16):2349-52. PubMed ID: 10476867
[TBL] [Abstract][Full Text] [Related]
8. Synthesis and dopamine receptor modulating activity of lactam conformationally constrained analogues of Pro-Leu-Gly-NH2.
Sreenivasan U; Mishra RK; Johnson RL
J Med Chem; 1993 Jan; 36(2):256-63. PubMed ID: 8093736
[TBL] [Abstract][Full Text] [Related]
9. Modulation of high-affinity CNS dopamine D2 receptor by L-pro-L-leu-glycinamide (PLG) analogue 3(R)-(N-L-prolylamino)-2-oxo-1-pyrrolidineacetamide.
Mishra RK; Srivastava LK; Johnson RL
Prog Neuropsychopharmacol Biol Psychiatry; 1990; 14(5):821-7. PubMed ID: 1981396
[TBL] [Abstract][Full Text] [Related]
10. Dopamine receptor modulation by a highly rigid spiro bicyclic peptidomimetic of Pro-Leu-Gly-NH2.
Genin MJ; Mishra RK; Johnson RL
J Med Chem; 1993 Oct; 36(22):3481-3. PubMed ID: 7901418
[TBL] [Abstract][Full Text] [Related]
11. Synthesis and dopamine receptor modulating activity of novel peptidomimetics of L-prolyl-L-leucyl-glycinamide featuring alpha,alpha-disubstituted amino acids.
Evans MC; Pradhan A; Venkatraman S; Ojala WH; Gleason WB; Mishra RK; Johnson RL
J Med Chem; 1999 Apr; 42(8):1441-7. PubMed ID: 10212130
[TBL] [Abstract][Full Text] [Related]
12. Pharmacological activities of the MIF-1 analogues Pro-Leu-Gly, Tyr-Pro-Leu-Gly and pareptide.
Mycroft FJ; Bhargava HN; Wei ET
Peptides; 1987; 8(6):1051-5. PubMed ID: 2894644
[TBL] [Abstract][Full Text] [Related]
13. Down-regulation of haloperidol-induced striatal dopamine receptor supersensitivity by active analogues of L-prolyl-L-leucyl-glycinamide (PLG).
Rajakumar G; Naas F; Johnson RL; Chiu S; Yu KL; Mishra RK
Peptides; 1987; 8(5):855-61. PubMed ID: 2893360
[TBL] [Abstract][Full Text] [Related]
14. Synthesis and dopamine receptor modulating activity of 3-substituted gamma-lactam peptidomimetics of L-prolyl-L-leucyl-glycinamide.
Dolbeare K; Pontoriero GF; Gupta SK; Mishra RK; Johnson RL
J Med Chem; 2003 Feb; 46(5):727-33. PubMed ID: 12593653
[TBL] [Abstract][Full Text] [Related]
15. Interaction of L-prolyl-L-leucyl glycinamide with dopamine D2 receptor: evidence for modulation of agonist affinity states in bovine striatal membranes.
Srivastava LK; Bajwa SB; Johnson RL; Mishra RK
J Neurochem; 1988 Mar; 50(3):960-8. PubMed ID: 2892892
[TBL] [Abstract][Full Text] [Related]
16. Design and synthesis of photoaffinity-labeling ligands of the L-prolyl-L-leucylglycinamide binding site involved in the allosteric modulation of the dopamine receptor.
Fisher A; Mann A; Verma V; Thomas N; Mishra RK; Johnson RL
J Med Chem; 2006 Jan; 49(1):307-17. PubMed ID: 16392815
[TBL] [Abstract][Full Text] [Related]
17. Tripeptide analogues of melanocyte-stimulating hormone release-inhibiting hormone (Pro-Leu-Gly-NH2) as inhibitors of oxotremorine-induced tremor.
Björkman S; Castensson S; Sievertsson H
J Med Chem; 1979 Aug; 22(8):931-5. PubMed ID: 40028
[TBL] [Abstract][Full Text] [Related]
18. Protection against MPTP treatment by an analog of Pro-Leu-Gly-NH2 (PLG, MIF-1).
Marcotte ER; Chugh A; Mishra RK; Johnson RL
Peptides; 1998; 19(2):403-6. PubMed ID: 9493876
[TBL] [Abstract][Full Text] [Related]
19. Structure activity relationship studies with hypothalamic peptide hormones III. Effect of melanotropin-release inhibiting factor and analogs on tolerance to morphine in the rat.
Bhargava HN; Kim HS
Neuropharmacology; 1982 Sep; 21(9):917-22. PubMed ID: 6128692
[TBL] [Abstract][Full Text] [Related]
20. Identification of dopamine "D3" and "D4" binding sites, labelled with [3H]2-amino-6,7-dihydroxy-1,2,3,4-tetrahydronaphthalene, as high agonist affinity states of the D1 and D2 dopamine receptors, respectively.
Urwyler S; Markstein R
J Neurochem; 1986 Apr; 46(4):1058-67. PubMed ID: 2936868
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
